New data at ESC Congress 2021 shows Repatha improves features of plaque stability in patients with acute coronary syndrome.- Amgen
Amgen announced positive data from the HUYGENS Phase III study showing that Repatha(evolocumab) in addition to optimized statin therapy, in comparison with optimized statin therapy alone, significantly improved features of plaque stability in patients with coronary artery disease (CAD). These data are being presented during an oral presentation at ESC Congress 2021, organized by the European Society of Cardiology, Aug. 27-30.